Stefan Evers
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Molecular Medicine top 5%
Papers in
- Oncology 19
- Peptidase Inhibition and Analysis 11
- Cancer Immunotherapy and Biomarkers 11
-
- RNA and protein synthesis mechanisms 5
- Glycosylation and Glycoproteins Research 3
- Co-authors
- Vaios Karanikas (1 shared paper)Priti S. Hegde (1 shared paper)Patrice Courvalin (4 shared papers)Richard Quintiliani (2 shared papers)Hanno Langen (6 shared papers)Wolfgang Keck (6 shared papers)Christopher P. Gray (5 shared papers)Béla Takács (3 shared papers)
- Journals
- PROTEOMICS (5 papers)Annals of Oncology (5 papers)Cancer Research (4 papers)Electrophoresis (4 papers)Journal of Clinical Oncology (3 papers)
- Partner nations
- SwitzerlandGermanyFrance
In The Last Decade
Stefan Evers
47 papers receiving 2.4k citations
Stefan Evers's Hit Papers
Peers
Comparison fields: 5 of 116
- Oncology 714
- Molecular Medicine 128
- Clinical Biochemistry 155
- Immunology 444
- Infectious Diseases 367
Countries citing papers authored by Stefan Evers
This map shows the geographic impact of Stefan Evers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Evers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Evers more than expected).
Fields of papers citing papers by Stefan Evers
This network shows the impact of papers produced by Stefan Evers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Evers. The network helps show where Stefan Evers may publish in the future.
Co-authors
The 25 scholars most cited alongside Stefan Evers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition Hit paper breakdown → | 2016 | 706 |
| 2 | 1993 | 145 | |
| 3 | 2001 | 130 | |
| 4 | 2000 | 128 | |
| 5 | 2001 | 109 | |
| 6 | 1993 | 104 | |
| 7 | 1996 | 98 | |
| 8 | 2004 | 93 | |
| 9 | 1994 | 81 | |
| 10 | 2004 | 76 | |
| 11 | 2004 | 72 | |
| 12 | 2010 | 68 | |
| 13 | 1997 | 66 | |
| 14 | 2018 | 60 | |
| 15 | 1998 | 58 | |
| 16 | 2008 | 56 | |
| 17 | 2001 | 50 | |
| 18 | 2012 | 49 | |
| 19 | 2002 | 43 | |
| 20 | 2018 | 36 |
About Stefan Evers
Stefan Evers is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Biotechnology and Spectroscopy, having authored 49 papers that have together received 2.5k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (11 papers), Cancer Immunotherapy and Biomarkers (11 papers), Monoclonal and Polyclonal Antibodies Research (10 papers), Radiopharmaceutical Chemistry and Applications (7 papers), Cancer Research and Treatments (6 papers), Advanced Proteomics Techniques and Applications (5 papers), RNA and protein synthesis mechanisms (5 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Oncology (714 citations), Molecular Medicine (128 citations), Clinical Biochemistry (155 citations), Immunology (444 citations) and Infectious Diseases (367 citations). Stefan Evers has collaborated with scholars based in Switzerland, Germany and France. Frequent co-authors include Vaios Karanikas, Priti S. Hegde, Patrice Courvalin, Richard Quintiliani, Hanno Langen, Wolfgang Keck, Christopher P. Gray, Béla Takács, Peter E. Reynolds and Michael Fountoulakis. Their work appears in journals such as PROTEOMICS, Annals of Oncology, Cancer Research, Electrophoresis and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.